Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bitopertin (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Roche

    • Most Recent Events

    • 11 Sep 2012 Results published in Clinical Therapeutics.
    • 12 Aug 2012 Primary endpoint 'noninferiority between bitopertin and placebo in QT-interval changes at steady state' has been met.
    • 08 Jun 2012 New source identified and integrated: ClinicalTrials.gov record NCT01613040.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top